NEA Management Company, LLC
NEA Management Company, LLC reported 26 US-listed holdings worth $1.59 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Trevi Therapeutics Inc. (15.5%), MBX Biosciences Inc. (12.6%) and Monte Rosa Therapeutics Inc. (11.7%). Against the quarter before, it opened 1 position, added to 0, trimmed 2 and sold out of 1.
Reported holdings$1.59B-9.7% on Q1 2026
Positions26as many as Q1 2026
The largest ten89.8%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
HeldTrimmed
The 14 largest of its 26 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 1Held 23Trimmed 2Sold out 1
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Karyopharm Therapeutics Inc. KPTI$5.6 million
Trimmed 2
- Celcuity Inc. CELC-575,000 shares · -25%
- Cvrx Inc. CVRX-71,643 shares · -4%
Sold out of 1
- Arcellx Inc. ACLX$349.7 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Trevi Therapeutics Inc. TRVI | 13,222,228 | $246.6 million | 15.53% | no change |
| MBX Biosciences Inc. MBX | 3,614,486 | $199.5 million | 12.56% | no change |
| Monte Rosa Therapeutics Inc. GLUE | 7,692,298 | $186.2 million | 11.72% | no change |
| Celcuity Inc. CELC | 1,710,561 | $179.0 million | 11.27% | -575,000 |
| Spyglass Pharma Inc. SGP | 7,392,301 | $164.6 million | 10.36% | no change |
| Savara Inc. SVRA | 24,471,264 | $150.7 million | 9.49% | no change |
| Zenas Biopharma Inc. ZBIO | 4,023,219 | $102.1 million | 6.43% | no change |
| Coursera Inc. COUR | 12,867,769 | $72.6 million | 4.57% | no change |
| Aurinia Pharmaceuticals Inc. AUPH | 3,969,834 | $67.4 million | 4.24% | no change |
| Crispr Therapeutics AG CRSP | 1,058,570 | $57.7 million | 3.64% | no change |
| Oric Pharmaceuticals Inc. ORIC | 4,118,621 | $44.6 million | 2.81% | no change |
| Phathom Pharmaceuticals Inc. PHAT | 1,960,169 | $21.3 million | 1.34% | no change |
| Korro Bio Inc. KRRO | 1,297,893 | $17.1 million | 1.08% | no change |
| X4 Pharmaceuticals Inc. | 3,233,743 | $15.1 million | 0.95% | no change |
| Champions Oncology Inc. CSBR | 1,713,720 | $10.6 million | 0.66% | no change |
| Nkarta Inc. NKTX | 3,568,781 | $10.1 million | 0.64% | no change |
| Cvrx Inc. CVRX | 1,954,440 | $10.0 million | 0.63% | -71,643 |
| Black Diamond Therapeutics I BDTX | 4,448,757 | $8.2 million | 0.52% | no change |
| Karyopharm Therapeutics Inc. KPTI | 576,780 | $5.6 million | 0.35% | new |
| Inventiva SA IVA | 1,462,586 | $5.5 million | 0.35% | no change |
| Athira Pharma Inc. LONA | 464,398 | $4.3 million | 0.27% | no change |
| Senti Biosciences Inc. SNTI | 3,775,615 | $4.2 million | 0.26% | no change |
| Marker Therapeutics Inc. MRKR | 1,625,678 | $2.4 million | 0.15% | no change |
| Onkure Therapeutics Inc OKUR | 478,548 | $2.2 million | 0.14% | no change |
| Imagenebio Inc. IMA | 50,005 | $295,030 | 0.02% | no change |
| Gossamer Bio Inc. GOSS | 1,000,000 | $164,600 | 0.01% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.